Stock Track | Inventiva S.A. Soars 6.70% in Pre-market Ahead of Q2 Earnings Report

Stock Track

Sep 25

Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market closes. The biopharmaceutical company, which focuses on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases, has captured the attention of market participants ahead of its financial disclosure.

The significant pre-market rally suggests that investors may be optimistic about Inventiva's upcoming results. According to FactSet Research Systems Inc., analysts expect the company to report a loss of $0.63 per share for the quarter. However, the strong stock movement indicates that market sentiment might be leaning towards the possibility of better-than-expected results or positive updates on the company's drug pipeline.

As Inventiva S.A. prepares to unveil its financial performance, investors will be closely watching for any updates on the company's lead drug candidate, lanifibranor, which is currently in Phase III clinical trials for NASH. The earnings report may provide crucial insights into the progress of ongoing studies and potential milestones, which could further influence the stock's performance in the coming days.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1140382844"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140382844\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140382844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-25 18:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140382844","market":"us","top_or_hot":-1,"title":"Stock Track | Inventiva S.A. Soars 6.70% in Pre-market Ahead of Q2 Earnings Report","media":"Stock Track","content":"<p>Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market closes. The biopharmaceutical company, which focuses on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases, has captured the attention of market participants ahead of its financial disclosure.</p>\n\n<p>The significant pre-market rally suggests that investors may be optimistic about Inventiva's upcoming results. According to FactSet Research Systems Inc., analysts expect the company to report a loss of $0.63 per share for the quarter. However, the strong stock movement indicates that market sentiment might be leaning towards the possibility of better-than-expected results or positive updates on the company's drug pipeline.</p>\n\n<p>As Inventiva S.A. prepares to unveil its financial performance, investors will be closely watching for any updates on the company's lead drug candidate, lanifibranor, which is currently in Phase III clinical trials for NASH. The earnings report may provide crucial insights into the progress of ongoing studies and potential milestones, which could further influence the stock's performance in the coming days.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Inventiva S.A. Soars 6.70% in Pre-market Ahead of Q2 Earnings Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Inventiva S.A. Soars 6.70% in Pre-market Ahead of Q2 Earnings Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-09-25 18:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market closes. The biopharmaceutical company, which focuses on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases, has captured the attention of market participants ahead of its financial disclosure.</p>\n\n<p>The significant pre-market rally suggests that investors may be optimistic about Inventiva's upcoming results. According to FactSet Research Systems Inc., analysts expect the company to report a loss of $0.63 per share for the quarter. However, the strong stock movement indicates that market sentiment might be leaning towards the possibility of better-than-expected results or positive updates on the company's drug pipeline.</p>\n\n<p>As Inventiva S.A. prepares to unveil its financial performance, investors will be closely watching for any updates on the company's lead drug candidate, lanifibranor, which is currently in Phase III clinical trials for NASH. The earnings report may provide crucial insights into the progress of ongoing studies and potential milestones, which could further influence the stock's performance in the coming days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IVA","symbol_name":"Inventiva S.A.","start_time":0,"source_url":"","article_id":"1140382844","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140382844","pubTimestamp":1758796699,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IVA":"Inventiva S.A."},"translate_title":"股票追踪|Inventiva S.A.在第二季度财报发布前盘前飙升6.70%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IVA":1},"content_text":"Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market closes. The biopharmaceutical company, which focuses on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases, has captured the attention of market participants ahead of its financial disclosure.\nThe significant pre-market rally suggests that investors may be optimistic about Inventiva's upcoming results. According to FactSet Research Systems Inc., analysts expect the company to report a loss of $0.63 per share for the quarter. However, the strong stock movement indicates that market sentiment might be leaning towards the possibility of better-than-expected results or positive updates on the company's drug pipeline.\nAs Inventiva S.A. prepares to unveil its financial performance, investors will be closely watching for any updates on the company's lead drug candidate, lanifibranor, which is currently in Phase III clinical trials for NASH. The earnings report may provide crucial insights into the progress of ongoing studies and potential milestones, which could further influence the stock's performance in the coming days.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}